Advertisement
Review Article| Volume 43, ISSUE 4, P579-590, December 2022

Toward a Broader Understanding of Cystic Fibrosis Epidemiology and Its Impact on Clinical Manifestations

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Chest Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Riordan J.R.
        • Rommens J.M.
        • Kerem B.
        • et al.
        Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.
        Science. 1989; 245: 1066-1073
        • Davis P.B.
        Cystic fibrosis since 1938.
        Am J Respir Crit Care Med. 2006; 173: 475-482
        • LeGrys V.A.
        • Yankaskas J.R.
        • Quittell L.M.
        • et al.
        Diagnostic sweat testing: the cystic fibrosis foundation guidelines.
        J Pediatr. 2007; 151: 85-89
        • Farrell P.
        • Joffe S.
        • Foley L.
        • et al.
        Diagnosis of cystic fibrosis in the republic of Ireland: epidemiology and costs.
        Ir Med J. 2007; 100: 557-560
        • Southern K.W.
        • Munck A.
        • Pollitt R.
        • et al.
        A survey of newborn screening for cystic fibrosis in Europe.
        J Cyst Fibros. 2007; 6: 57-65
        • Scotet V.
        • Gutierrez H.
        • Farrell P.M.
        Newborn screening for CF across the Globe—where is it worthwhile?.
        Int J Neonatal Screen. 2020; 6: 18
        • Lilley M.
        • Christian S.
        • Hume S.
        • et al.
        Newborn screening for cystic fibrosis in Alberta: two years of experience.
        Paediatr Child Health. 2010; 15: 590-594
      1. 2019 Annual data report. cystic fibrosis foundation patient registry.
        (Available at:) (Accessed November 21, 2021)
        • Hamosh A.
        • FitzSimmons S.C.
        • Macek Jr., M.
        • et al.
        Comparison of the clinical manifestations of cystic fibrosis in black and white patients.
        J Pediatr. 1998; 132: 225-259
        • Palomaki G.E.
        • FitzSimmons S.C.
        • Haddow J.E.
        Clinical sensitivity of prenatal screening for cystic fibrosis via CFTR carrier testing in a United States panethnic population.
        Genet Med. 2004; 6: 405-414
        • Klinger K.W.
        Cystic fibrosis in the Ohio amish: gene frequency and founder effect.
        Hum Genet. 1983; 65: 94-98
        • Nazer H.M.
        Early diagnosis of cystic fibrosis in jordanian children.
        J Trop Pediatr. 1992; 38: 113-115
        • Stafler P.
        • Mei-Zahav M.
        • Wilschanski M.
        • et al.
        The impact of a national population carrier screening program on cystic fibrosis birth rate and age at diagnosis: implications for newborn screening.
        J Cyst Fibros. 2016; 15: 460-466
        • Powers C.A.
        • Potter E.M.
        • Wessel H.U.
        • et al.
        Cystic fibrosis in Asian Indians.
        Arch Pediatr Adolesc Med. 1996; 150: 554-555
        • Kapoor V.
        • Shastri S.S.
        • Kabra M.
        • et al.
        Carrier frequency of F508del mutation of cystic fibrosis in Indian population.
        J Cyst Fibros. 2006; 5: 43-46
        • Kabra S.K.
        • Kabra M.
        • Lodha R.
        • et al.
        Cystic fibrosis in India.
        Pediatr Pulmonol. 2007; 42: 1087-1094
        • Yamashiro Y.
        • Shimizu T.
        • Oguchi S.
        • et al.
        The estimated incidence of cystic fibrosis in Japan.
        J Pediatr Gastroenterol Nutr. 1997; 24: 544-547
      2. 2019 annual data report. the cystic fibrosis registry of Ireland.
        (Available at:) (Accessed November 17, 2021)
        • McKone E.F.
        • Ariti C.
        • Jackson A.
        • et al.
        Survival estimates in European cystic fibrosis patients and the impact of socioeconomic factors: a retrospective registry cohort study.
        Eur Respir J. 2021; 582002288
        • Stephenson A.L.
        • Sykes J.
        • Stanojevic S.
        • et al.
        Survival comparison of patients with cystic fibrosis in Canada and the United States: a population-based cohort study.
        Ann Intern Med. 2017; 166: 537-546
        • Di Sant’Agnese P.A.
        • Darling R.C.
        • Perera G.A.
        • et al.
        Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas; clinical significance and relationship to the disease.
        Pediatrics. 1953; 12: 549-563
        • Gregg R.G.
        • Wilfond B.S.
        • Farrell P.M.
        • et al.
        Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols.
        Am J Hum Genet. 1993; 52: 616-626
        • Farrell P.M.
        • Kosorok M.R.
        • Rock M.J.
        • et al.
        Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth.
        Pediatrics. 2001; 107: 1-13
        • Grosse S.
        • Boyle C.
        • Botkin J.
        • et al.
        Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs.
        MMWR Recomm Rep. 2004; 53: 1-36
        • Farrell P.M.
        • White T.B.
        • Ren C.L.
        • et al.
        Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation.
        J Pediatr. 2017; 181S: S4-S15
        • Hale J.E.
        • Parad R.B.
        • Comeau A.M.
        Newborn screening showing decreasing incidence of cystic fibrosis.
        N Engl J Med. 2008; 358: 973-974
        • Sontag M.K.
        • Wagener J.S.
        • Accurso F.
        • et al.
        Consistent incidence of cystic fibrosis in a long-term newborn screen population.
        Pediatr Pulmonol. 2008; 43: 272
        • Parker-McGill K.
        • Nugent M.
        • Bersie R.
        • et al.
        Changing incidence of cystic fibrosis in Wisconsin, USA.
        Pediatr Pulmonol. 2015; 50: 1065-1072
        • Castellani C.
        • Picci L.
        • Tamanini A.
        • et al.
        Association between carrier screening and incidence of cystic fibrosis.
        JAMA. 2009; 302: 2573
        • De Boeck K.
        Cystic fibrosis in the year 2020: a disease with a new face.
        Acta Paediatr. 2020; 109: 892-899
        • Cystic Fibrosis Foundation Patient Registry
        1999 annual data report.
        Cystic Fibrosis Foundation, Bethesda, Maryland2000
        • Cystic Fibrosis Foundation Patient Registry
        2009 annual data report.
        Cystic Fibrosis Foundation, Bethesda, Maryland2010
        • Davis P.B.
        • Schluchter M.D.
        • Konstan M.W.
        Relation of sweat chloride concentration to severity of lung disease in cystic fibrosis.
        Pediatr Pulmonol. 2004; 38: 204-209
        • Cutting G.R.
        Modifier genetics: cystic fibrosis.
        Annu Rev Genomics Hum Genet. 2005; 6: 237-260
        • O’Neal W.K.
        • Knowles M.R.
        Cystic fibrosis disease modifiers: complex genetics defines the phenotypic diversity in a monogenic disease.
        Annu Rev Genomics Hum Genet. 2018; 19: 201-222
        • Konstan M.W.
        • Schluchter M.D.
        • Xue W.
        • et al.
        Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis.
        Am J Respir Crit Care Med. 2007; 176: 1084-1089
        • Konstan M.W.
        • VanDevanter D.R.
        • Sawicki G.S.
        • et al.
        Association of high-dose ibuprofen use, lung function decline, and long-term survival in children with cystic fibrosis.
        Ann Am Thorac Soc. 2018; 15: 485-493
        • Saiman L.
        • Marshall B.C.
        • Mayer-Hamblett N.
        • et al.
        Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa.
        JAMA. 2003; 290: 1749
        • Chambers D.C.
        • Cherikh W.S.
        • Goldfarb S.B.
        • et al.
        The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-fifth adult lung and heart-lung transplant report—2018; focus theme: multi-organ transplantation.
        J Heart Lung Transplant. 2018; 37: 1169-1183
        • Ramos K.J.
        • Quon B.S.
        • Heltshe S.L.
        • et al.
        Heterogeneity in survival in adult patients with cystic fibrosis with FEV1 < 30% of predicted in the United States.
        Chest. 2017; 151: 1320-1328
        • Ramsey B.W.
        • Davies J.
        • McElvaney N.G.
        • et al.
        A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.
        N Engl J Med. 2011; 365: 1663-1672
        • Durmowicz T.
        • Pacanowski M.
        Novel approach allows expansion of indication for cystic fibrosis drug. In: Spotlight on center for drug evaluation and research science.
        (Available at:) (Accessed: November 27, 2021)
        • Clancy J.
        • Cotton C.
        • Donaldson S.
        • et al.
        CFTR modulator theratyping: current status, gaps and future directions.
        J Cyst Fibros. 2019; 18: 22-34
        • Wainwright C.E.
        • Elborn J.S.
        • Ramsey B.W.
        • et al.
        Lumacaftor–Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR.
        N Engl J Med. 2015; 373: 220-231
        • Taylor-Cousar J.L.
        • Munck A.
        • McKone E.F.
        • et al.
        Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.
        N Engl J Med. 2017; 377: 2013-2023
        • Middleton P.G.
        • Mall M.A.
        • Dřevínek P.
        • et al.
        Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
        N Engl J Med. 2019; 381: 1809-1819
        • Sawicki G.S.
        • McKone E.F.
        • Pasta D.J.
        • et al.
        Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data.
        Am J Respir Crit Care Med. 2015; 192: 836-842
        • Guimbellot J.S.
        • Baines A.
        • Paynter A.
        • et al.
        Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.
        J Cyst Fibros. 2021; 20: 213-219
        • Konstan M.W.
        • McKone E.F.
        • Moss R.B.
        • et al.
        Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
        Lancet Respir Med. 2017; 5: 107-118
        • Flume P.A.
        • Biner R.F.
        • Downey D.G.
        • et al.
        Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
        Lancet Respir Med. 2021; 9: 733-746
        • Bobadilla J.L.
        • Macek M.
        • Fine J.P.
        • et al.
        Cystic Fibrosis: a worldwide analysis of CFTR mutations -- correlation with incidence data and application to screening.
        Hum Mutat. 2002; 19: 575-606
        • McGarry M.E.
        • Williams 2nd, W.A.
        • McColley S.A.
        The demographics of adverse outcomes in cystic fibrosis.
        Pediatr Pulmonol. 2019; 54: S74-S83
        • Rho J.
        • Ahn C.
        • Gao A.
        • et al.
        Disparities in mortality of hispanic patients with cystic fibrosis in the United States. A national and regional cohort study.
        Am J Respir Crit Care Med. 2018; 198: 1055-1063
        • McGarry M.E.
        • Neuhaus J.M.
        • Nielson D.W.
        • et al.
        Pulmonary function disparities exist and persist in Hispanic patients with cystic fibrosis: a longitudinal analysis.
        Pediatr Pulmonol. 2017; 52: 1550-1557
        • McGarry M.E.
        • Neuhaus J.M.
        • Nielson D.W.
        • et al.
        Regional variations in longitudinal pulmonary function: a comparison of Hispanic and non-Hispanic subjects with cystic fibrosis in the United States.
        Pediatr Pulmonol. 2019; 54: 1382-1390
        • Pique L.
        • Graham S.
        • Pearl M.
        • et al.
        Cystic fibrosis newborn screening programs: implications of the CFTR variant spectrum in nonwhite patients.
        Genet Med. 2016; 19: 36-44
        • Accurso F.J.
        • Sontag M.K.
        • Wagener J.S.
        Complications associated with symptomatic diagnosis in infants with cystic fibrosis.
        J Pediatr. 2005; 147: S37-S41
        • Campbell P.W.
        • White T.B.
        Newborn screening for cystic fibrosis: an opportunity to improve care and outcomes.
        J Pediatr. 2005; 147: S2-S5
        • McGarry M.E.
        • McColley S.A.
        Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype.
        Pediatr Pulmonol. 2021; 56: 1496-1503
        • Thomassen M.J.
        • Demko C.A.
        • Klinger J.D.
        • et al.
        Pseudomonas cepacia colonization among patients with cystic fibrosis.
        Am Rev Respir Dis. 1985; 131: 791-796
        • Floto R.A.
        • Olivier K.N.
        • Saiman L.
        • et al.
        US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis.
        Thorax. 2016; 71: i1-i22
        • McClenaghan E.
        • Cosgriff R.
        • Brownlee K.
        • et al.
        The global impact of SARS-CoV-2 in 181 people with cystic fibrosis.
        J Cyst Fibros. 2020; 19: 868-871
        • Hadi Y.B.
        • Lakhani D.A.
        • Naqvi S.F.
        • et al.
        Outcomes of SARS-CoV-2 infection in patients with cystic fibrosis: a multicenter retrospective research network study.
        Respir Med. 2021; 188: 106606
        • Cystic Fibrosis Foundation Patient Registry
        2016 center specific data report.
        Cystic Fibrosis Foundation, Bethesda, Maryland2017
        • Sharma R.
        Wasting as an independent predictor of mortality in patients with cystic fibrosis.
        Thorax. 2001; 56: 746-750
        • Beker L.T.
        • Russek-Cohen E.
        • Fink R.J.
        Stature as a prognostic factor in cystic fibrosis survival.
        J Am Diet Assoc. 2001; 101: 438-442
        • Vieni G.
        • Faraci S.
        • Collura M.
        • et al.
        Stunting is an independent predictor of mortality in patients with cystic fibrosis.
        Clin Nutr. 2013; 32: 382-385
        • Taylor-Cousar J.L.
        CFTR modulators: impact on fertility, pregnancy, and lactation in women with cystic fibrosis.
        J Clin Med. 2020; 9: 2706
        • Nash E.F.
        • Middleton P.G.
        • Taylor-Cousar J.L.
        Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators – an international survey.
        J Cyst Fibros. 2020; 19: 521-526
        • Fortner C.N.
        • Seguin J.M.
        • Kay D.M.
        Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy.
        J Cyst Fibros. 2021; 20: 835-836
        • Lai S.
        • Mazzaferro S.
        • Mitterhofer A.P.
        • et al.
        Renal involvement and metabolic alterations in adults patients affected by cystic fibrosis.
        J Transl Med. 2019; 17: 388
        • Tarshish Y.
        • Huang L.
        • Jackson F.I.
        • et al.
        Risk factors for hearing loss in patients with cystic fibrosis.
        J Am Acad Audiol. 2016; 27: 6-12
        • Garwood S.
        • Flume P.A.
        • Ravenel J.
        Superior vena cava syndrome related to indwelling intravenous catheters in patients with cystic fibrosis.
        Pediatr Pulmonol. 2006; 41: 683-687
        • Hadjiliadis D.
        • Khoruts A.
        • Zauber A.G.
        • et al.
        Cystic fibrosis colorectal cancer screening consensus recommendations.
        Gastroenterology. 2018; 154: 736-745
        • Hull J.H.
        • Garrod R.
        • Ho T.B.
        • et al.
        Increased augmentation index in patients with cystic fibrosis.
        Eur Respir J. 2009; 34: 1322-1328
        • Macnee W.
        Premature vascular ageing in cystic fibrosis.
        Eur Respir J. 2009; 34: 1217-1218
        • Bezzerri V.
        • Piacenza F.
        • Caporelli N.
        • et al.
        Is cellular senescence involved in cystic fibrosis?.
        Respir Res. 2019; 20: 32